{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:01:21Z","timestamp":1793898081222,"version":"4.8.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA263304"],"award-info":[{"award-number":["K08CA263304"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32CA203703-09"],"award-info":[{"award-number":["5T32CA203703-09"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11523-024-01097-2","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:10:36Z","timestamp":1726243836000},"page":"845-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics"],"prefix":"10.1007","volume":"19","author":[{"given":"Lawrence W.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Joo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Fazlollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra W.","family":"Ryeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-8590","authenticated-orcid":false,"given":"Ryan H.","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"3","key":"1097_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1097_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Lauren","year":"1965","unstructured":"Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31\u201349. https:\/\/doi.org\/10.1111\/apm.1965.64.1.31.","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"1","key":"1097_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12253-015-9996-6","volume":"22","author":"YC Chen","year":"2016","unstructured":"Chen YC, Fang WL, Wang RF, Liu CA, Yang MH, Lo SS, et al. Clinicopathological variation of Lauren classification in gastric cancer. Pathol Oncol Res. 2016;22(1):197\u2013202. https:\/\/doi.org\/10.1007\/s12253-015-9996-6.","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"1097_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188719","volume":"1877","author":"JL Monster","year":"2022","unstructured":"Monster JL, Kemp LJS, Gloerich M, van der Post RS. Diffuse gastric cancer: emerging mechanisms of tumor initiation and progression. Biochim Biophys Acta Rev Cancer. 2022;1877(3): 188719. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188719.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1097_CR5","volume-title":"Digestive system tumours: WHO classification of tumours","author":"WHO Classification of Tumours","year":"2019","unstructured":"WHO Classification of Tumours. Digestive system tumours: WHO classification of tumours, vol. 1. Geneva: World Health Organization; 2019."},{"issue":"1","key":"1097_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.21037\/jgo.2017.01.10","volume":"8","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, et al. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 2017;8(1):148\u201363. https:\/\/doi.org\/10.21037\/jgo.2017.01.10.","journal-title":"J Gastrointest Oncol."},{"issue":"9","key":"1097_CR7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1007\/s00268-002-6344-2","volume":"26","author":"D Marrelli","year":"2002","unstructured":"Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Different patterns of recurrence in gastric cancer depending on Lauren\u2019s histological type: longitudinal study. World J Surg. 2002;26(9):1160\u20135. https:\/\/doi.org\/10.1007\/s00268-002-6344-2.","journal-title":"World J Surg"},{"issue":"1","key":"1097_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/SLA.0000000000002040","volume":"267","author":"JH Lee","year":"2018","unstructured":"Lee JH, Chang KK, Yoon C, Tang LH, Strong VE, Yoon SS. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Ann Surg. 2018;267(1):105\u201313. https:\/\/doi.org\/10.1097\/SLA.0000000000002040.","journal-title":"Ann Surg"},{"key":"1097_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101846","volume":"69","author":"WJ Koemans","year":"2020","unstructured":"Koemans WJ, Luijten J, van der Kaaij RT, Grootscholten C, Snaebjornsson P, Verhoeven RHA, et al. The metastatic pattern of intestinal and diffuse type gastric carcinoma\u2014a Dutch national cohort study. Cancer Epidemiol. 2020;69: 101846. https:\/\/doi.org\/10.1016\/j.canep.2020.101846.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"1097_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cncr.33213","volume":"127","author":"N Setia","year":"2021","unstructured":"Setia N, Wang CX, Lager A, Maron S, Shroff S, Arndt N, et al. Morphologic and molecular analysis of early-onset gastric cancer. Cancer. 2021;127(1):103\u201314. https:\/\/doi.org\/10.1002\/cncr.33213.","journal-title":"Cancer"},{"issue":"6","key":"1097_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.5009\/gnl17033","volume":"11","author":"JY Lee","year":"2017","unstructured":"Lee JY, Gong EJ, Chung EJ, Park HW, Bae SE, Kim EH, et al. The characteristics and prognosis of diffuse-type early gastric cancer diagnosed during health check-ups. Gut Liver. 2017;11(6):807\u201312. https:\/\/doi.org\/10.5009\/gnl17033.","journal-title":"Gut Liver"},{"issue":"7","key":"1097_CR12","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1158\/1055-9965.EPI-09-0250","volume":"18","author":"H Wu","year":"2009","unstructured":"Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomark Prev. 2009;18(7):1945\u201352. https:\/\/doi.org\/10.1158\/1055-9965.EPI-09-0250.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"7","key":"1097_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5858\/2004-128-765-DTITIA","volume":"128","author":"DE Henson","year":"2004","unstructured":"Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973\u20132000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128(7):765\u201370. https:\/\/doi.org\/10.5858\/2004-128-765-DTITIA.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"1097_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338\u201349. https:\/\/doi.org\/10.1038\/s41571-023-00747-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1097_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/jnci\/83.9.640","volume":"83","author":"J Parsonnet","year":"1991","unstructured":"Parsonnet J, Vandersteen D, Goates J, Sibley RK, Pritikin J, Chang Y. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst. 1991;83(9):640\u20133. https:\/\/doi.org\/10.1093\/jnci\/83.9.640.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1097_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ijc.10649","volume":"101","author":"S Sasazuki","year":"2002","unstructured":"Sasazuki S, Sasaki S, Tsugane S, Japan Public Health Center Study G. Cigarette smoking, alcohol consumption and subsequent gastric cancer risk by subsite and histologic type. Int J Cancer. 2002;101(6):560\u20136. https:\/\/doi.org\/10.1002\/ijc.10649.","journal-title":"Int J Cancer"},{"issue":"9","key":"1097_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1055-9965.EPI-22-0051","volume":"31","author":"J Jang","year":"2022","unstructured":"Jang J, Lee S, Ko KP, Abe SK, Rahman MS, Saito E, et al. Association between body mass index and risk of gastric cancer by anatomic and histologic subtypes in over 500,000 East and Southeast Asian Cohort Participants. Cancer Epidemiol Biomark Prev. 2022;31(9):1727\u201334. https:\/\/doi.org\/10.1158\/1055-9965.EPI-22-0051.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10","key":"1097_CR18","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/ijc.30891","volume":"141","author":"M Rota","year":"2017","unstructured":"Rota M, Pelucchi C, Bertuccio P, Matsuo K, Zhang ZF, Ito H, et al. Alcohol consumption and gastric cancer risk\u2014a pooled analysis within the StoP project consortium. Int J Cancer. 2017;141(10):1950\u201362. https:\/\/doi.org\/10.1002\/ijc.30891.","journal-title":"Int J Cancer"},{"issue":"3","key":"1097_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.gastro.2022.11.032","volume":"164","author":"OO Omofuma","year":"2023","unstructured":"Omofuma OO, Cook MB, Abnet CC, Camargo MC. Race and ethnicity, stage-specific mortality, and cancer treatment in esophageal and gastric cancers: surveillance, epidemiology, and end results (2000\u20132018). Gastroenterology. 2023;164(3):473\u20135. https:\/\/doi.org\/10.1053\/j.gastro.2022.11.032. (e4).","journal-title":"Gastroenterology"},{"issue":"9","key":"1097_CR20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/1055-9965.EPI-22-0210","volume":"31","author":"A Tavakkoli","year":"2022","unstructured":"Tavakkoli A, Pruitt SL, Hoang AQ, Zhu H, Hughes AE, McKey TA, et al. Ethnic disparities in early-onset gastric cancer: a population-based study in Texas and California. Cancer Epidemiol Biomark Prev. 2022;31(9):1710\u20139. https:\/\/doi.org\/10.1158\/1055-9965.EPI-22-0210.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"1097_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10120-016-0667-4","volume":"20","author":"H Jin","year":"2017","unstructured":"Jin H, Pinheiro PS, Callahan KE, Altekruse SF. Examining the gastric cancer survival gap between Asians and whites in the United States. Gastric Cancer. 2017;20(4):573\u201382. https:\/\/doi.org\/10.1007\/s10120-016-0667-4.","journal-title":"Gastric Cancer"},{"issue":"7517","key":"1097_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"issue":"15","key":"1097_CR23","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","volume":"23","author":"BH Sohn","year":"2017","unstructured":"Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017;23(15):4441\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2211.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1097_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449\u201356. https:\/\/doi.org\/10.1038\/nm.3850.","journal-title":"Nat Med"},{"issue":"1","key":"1097_CR25","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/s41467-018-04179-8","volume":"9","author":"SC Oh","year":"2018","unstructured":"Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018;9(1):1777. https:\/\/doi.org\/10.1038\/s41467-018-04179-8.","journal-title":"Nat Commun"},{"issue":"3","key":"1097_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","volume":"145","author":"Z Lei","year":"2013","unstructured":"Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145(3):554\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2013.05.010.","journal-title":"Gastroenterology"},{"issue":"2","key":"1097_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/gutjnl-2021-326483","volume":"72","author":"SWT Ho","year":"2023","unstructured":"Ho SWT, Sheng T, Xing M, Ooi WF, Xu C, Sundar R, et al. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut. 2023;72(2):226\u201341. https:\/\/doi.org\/10.1136\/gutjnl-2021-326483.","journal-title":"Gut"},{"issue":"1","key":"1097_CR28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41467-018-03121-2","volume":"9","author":"S Ge","year":"2018","unstructured":"Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng J, et al. A proteomic landscape of diffuse-type gastric cancer. Nat Commun. 2018;9(1):1012. https:\/\/doi.org\/10.1038\/s41467-018-03121-2.","journal-title":"Nat Commun"},{"issue":"3","key":"1097_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10120-019-01029-4","volume":"23","author":"SK Kim","year":"2020","unstructured":"Kim SK, Kim HJ, Park JL, Heo H, Kim SY, Lee SI, et al. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer. Gastric Cancer. 2020;23(3):473\u201382. https:\/\/doi.org\/10.1007\/s10120-019-01029-4.","journal-title":"Gastric Cancer"},{"issue":"23","key":"1097_CR30","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","volume":"65","author":"F van Roy","year":"2008","unstructured":"van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756\u201388. https:\/\/doi.org\/10.1007\/s00018-008-8281-1.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"1097_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bbcan.2012.05.002","volume":"1826","author":"J Paredes","year":"2012","unstructured":"Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 2012;1826(2):297\u2013311. https:\/\/doi.org\/10.1016\/j.bbcan.2012.05.002.","journal-title":"Biochim Biophys Acta"},{"issue":"55","key":"1097_CR32","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1038\/onc.2008.343","volume":"27","author":"A Jeanes","year":"2008","unstructured":"Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008;27(55):6920\u20139. https:\/\/doi.org\/10.1038\/onc.2008.343.","journal-title":"Oncogene"},{"issue":"1","key":"1097_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166(1):21\u201345. https:\/\/doi.org\/10.1016\/j.cell.2016.06.028.","journal-title":"Cell"},{"issue":"19","key":"1097_CR34","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/0008-5472.CAN-17-0061","volume":"77","author":"JE Till","year":"2017","unstructured":"Till JE, Yoon C, Kim BJ, Roby K, Addai P, Jonokuchi E, et al. Oncogenic KRAS and p53 loss drive gastric tumorigenesis in mice that can be attenuated by E-cadherin expression. Cancer Res. 2017;77(19):5349\u201359. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0061.","journal-title":"Cancer Res"},{"issue":"35","key":"1097_CR35","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1038\/s41388-018-0304-2","volume":"37","author":"AM Mendonsa","year":"2018","unstructured":"Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene. 2018;37(35):4769\u201380. https:\/\/doi.org\/10.1038\/s41388-018-0304-2.","journal-title":"Oncogene"},{"issue":"14","key":"1097_CR36","first-page":"3845","volume":"54","author":"KF Becker","year":"1994","unstructured":"Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54(14):3845\u201352.","journal-title":"Cancer Res"},{"issue":"7","key":"1097_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/jnci\/92.7.569","volume":"92","author":"G Tamura","year":"2000","unstructured":"Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 2000;92(7):569\u201373. https:\/\/doi.org\/10.1093\/jnci\/92.7.569.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1097_CR38","first-page":"2757","volume":"17","author":"H Rashid","year":"2016","unstructured":"Rashid H, Alam K, Afroze D, Yousuf A, Banday M, Kawoosa F. Hypermethylation status of E-cadherin gene in gastric cancer patients in a high incidence area. Asian Pac J Cancer Prev. 2016;17(6):2757\u201360.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1097_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","volume":"1","author":"S Hansford","year":"2015","unstructured":"Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2014.168.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1097_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ng.2984","volume":"46","author":"M Kakiuchi","year":"2014","unstructured":"Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46(6):583\u20137. https:\/\/doi.org\/10.1038\/ng.2984.","journal-title":"Nat Genet"},{"issue":"3","key":"1097_CR41","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/s0092-8674(00)81281-7","volume":"84","author":"TJ Mitchison","year":"1996","unstructured":"Mitchison TJ, Cramer LP. Actin-based cell motility and cell locomotion. Cell. 1996;84(3):371\u20139. https:\/\/doi.org\/10.1016\/s0092-8674(00)81281-7.","journal-title":"Cell"},{"issue":"3","key":"1097_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/s0092-8674(00)81280-5","volume":"84","author":"DA Lauffenburger","year":"1996","unstructured":"Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84(3):359\u201369. https:\/\/doi.org\/10.1016\/s0092-8674(00)81280-5.","journal-title":"Cell"},{"issue":"6","key":"1097_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ng.2983","volume":"46","author":"K Wang","year":"2014","unstructured":"Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573\u201382. https:\/\/doi.org\/10.1038\/ng.2983.","journal-title":"Nat Genet"},{"issue":"4","key":"1097_CR44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-15-1356","volume":"22","author":"C Yoon","year":"2016","unstructured":"Yoon C, Cho SJ, Aksoy BA, Park DJ, Schultz N, Ryeom SW, et al. Chemotherapy resistance in diffuse-type gastric adenocarcinoma is mediated by RhoA activation in cancer stem-like cells. Clin Cancer Res. 2016;22(4):971\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1356.","journal-title":"Clin Cancer Res"},{"issue":"816","key":"1097_CR45","doi-asserted-by":"publisher","first-page":"esdk9171","DOI":"10.1126\/scisignal.adk9171","volume":"16","author":"D Benton","year":"2023","unstructured":"Benton D, Chernoff J. RHOA drivers take alternate routes in gastric cancer. Sci Signal. 2023;16(816):esdk9171. https:\/\/doi.org\/10.1126\/scisignal.adk9171.","journal-title":"Sci Signal"},{"issue":"2","key":"1097_CR46","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-19-0811","volume":"10","author":"H Zhang","year":"2020","unstructured":"Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, et al. Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer. Cancer Discov. 2020;10(2):288\u2013305. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0811.","journal-title":"Cancer Discov"},{"issue":"3","key":"1097_CR47","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.trecan.2022.12.001","volume":"9","author":"J Barcelo","year":"2023","unstructured":"Barcelo J, Samain R, Sanz-Moreno V. Preclinical to clinical utility of ROCK inhibitors in cancer. Trends Cancer. 2023;9(3):250\u201363. https:\/\/doi.org\/10.1016\/j.trecan.2022.12.001.","journal-title":"Trends Cancer"},{"issue":"38","key":"1097_CR48","doi-asserted-by":"publisher","first-page":"13756","DOI":"10.3748\/wjg.v20.i38.13756","volume":"20","author":"T Matsuoka","year":"2014","unstructured":"Matsuoka T, Yashiro M. Rho\/ROCK signaling in motility and metastasis of gastric cancer. World J Gastroenterol. 2014;20(38):13756\u201366. https:\/\/doi.org\/10.3748\/wjg.v20.i38.13756.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1097_CR49","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1038\/s41467-018-06747-4","volume":"9","author":"H Yang","year":"2018","unstructured":"Yang H, Hong D, Cho SY, Park YS, Ko WR, Kim JH, et al. RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer. Nat Commun. 2018;9(1):4439. https:\/\/doi.org\/10.1038\/s41467-018-06747-4.","journal-title":"Nat Commun"},{"issue":"1","key":"1097_CR50","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41467-018-04907-0","volume":"9","author":"Y Shu","year":"2018","unstructured":"Shu Y, Zhang W, Hou Q, Zhao L, Zhang S, Zhou J, et al. Prognostic significance of frequent CLDN18-ARHGAP26\/6 fusion in gastric signet-ring cell cancer. Nat Commun. 2018;9(1):2447. https:\/\/doi.org\/10.1038\/s41467-018-04907-0.","journal-title":"Nat Commun"},{"issue":"4","key":"1097_CR51","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/cas.13967","volume":"110","author":"I Nakayama","year":"2019","unstructured":"Nakayama I, Shinozaki E, Sakata S, Yamamoto N, Fujisaki J, Muramatsu Y, et al. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults. Cancer Sci. 2019;110(4):1352\u201363. https:\/\/doi.org\/10.1111\/cas.13967.","journal-title":"Cancer Sci"},{"issue":"50","key":"1097_CR52","doi-asserted-by":"publisher","first-page":"29336","DOI":"10.18632\/oncotarget.25464","volume":"9","author":"A Tanaka","year":"2018","unstructured":"Tanaka A, Ishikawa S, Ushiku T, Yamazawa S, Katoh H, Hayashi A, et al. Frequent CLDN18-ARHGAP fusion in highly metastatic diffuse-type gastric cancer with relatively early onset. Oncotarget. 2018;9(50):29336\u201350. https:\/\/doi.org\/10.18632\/oncotarget.25464.","journal-title":"Oncotarget"},{"issue":"2","key":"1097_CR53","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.celrep.2015.06.020","volume":"12","author":"F Yao","year":"2015","unstructured":"Yao F, Kausalya JP, Sia YY, Teo AS, Lee WH, Ong AG, et al. Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity. Cell Rep. 2015;12(2):272\u201385. https:\/\/doi.org\/10.1016\/j.celrep.2015.06.020.","journal-title":"Cell Rep"},{"key":"1097_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-329686","author":"F Zhang","year":"2024","unstructured":"Zhang F, Sahu V, Peng K, Wang Y, Li T, Bala P, et al. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer. Gut. 2024. https:\/\/doi.org\/10.1136\/gutjnl-2023-329686.","journal-title":"Gut"},{"issue":"3","key":"1097_CR55","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cgh.2005.12.003","volume":"4","author":"V Blair","year":"2006","unstructured":"Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4(3):262\u201375. https:\/\/doi.org\/10.1016\/j.cgh.2005.12.003.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"1097_CR56","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/jmedgenet-2019-105991","volume":"56","author":"RM Xicola","year":"2019","unstructured":"Xicola RM, Li S, Rodriguez N, Reinecke P, Karam R, Speare V, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet. 2019;56(12):838\u201343. https:\/\/doi.org\/10.1136\/jmedgenet-2019-105991.","journal-title":"J Med Genet"},{"issue":"9","key":"1097_CR57","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2019.1208","volume":"5","author":"ME Roberts","year":"2019","unstructured":"Roberts ME, Ranola JMO, Marshall ML, Susswein LR, Graceffo S, Bohnert K, et al. Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol. 2019;5(9):1325\u201331. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1208.","journal-title":"JAMA Oncol"},{"issue":"11\u201312","key":"1097_CR58","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1038\/sj.bjc.6690308","volume":"79","author":"J Stone","year":"1999","unstructured":"Stone J, Bevan S, Cunningham D, Hill A, Rahman N, Peto J, et al. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer. 1999;79(11\u201312):1935\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6690308.","journal-title":"Br J Cancer"},{"issue":"5","key":"1097_CR59","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.gastro.2023.01.038","volume":"164","author":"L Decourtye-Espiard","year":"2023","unstructured":"Decourtye-Espiard L, Guilford P. Hereditary diffuse gastric cancer. Gastroenterology. 2023;164(5):719\u201335. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.038.","journal-title":"Gastroenterology"},{"issue":"6","key":"1097_CR60","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gut.2002.010447","volume":"53","author":"A Charlton","year":"2004","unstructured":"Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut. 2004;53(6):814\u201320. https:\/\/doi.org\/10.1136\/gut.2002.010447.","journal-title":"Gut"},{"issue":"6","key":"1097_CR61","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ccell.2015.10.003","volume":"28","author":"Y Hayakawa","year":"2015","unstructured":"Hayakawa Y, Ariyama H, Stancikova J, Sakitani K, Asfaha S, Renz BW, et al. Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. Cancer Cell. 2015;28(6):800\u201314. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.003.","journal-title":"Cancer Cell"},{"issue":"6","key":"1097_CR62","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-06-3021","volume":"67","author":"B Humar","year":"2007","unstructured":"Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res. 2007;67(6):2480\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3021.","journal-title":"Cancer Res"},{"issue":"8","key":"1097_CR63","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","volume":"21","author":"VR Blair","year":"2020","unstructured":"Blair VR, McLeod M, Carneiro F, Coit DG, D\u2019Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(20)30219-9.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1097_CR64","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/jmedgenet-2015-103094","volume":"52","author":"RS van der Post","year":"2015","unstructured":"van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361\u201374. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103094.","journal-title":"J Med Genet"},{"issue":"6","key":"1097_CR65","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s10120-022-01318-5","volume":"25","author":"G Roberts","year":"2022","unstructured":"Roberts G, Benusiglio PR, Bisseling T, Coit D, Davis JL, Grimes S, et al. International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the life after prophylactic total gastrectomy (LAP-TG) study. Gastric Cancer. 2022;25(6):1094\u2013104. https:\/\/doi.org\/10.1007\/s10120-022-01318-5.","journal-title":"Gastric Cancer"},{"issue":"11","key":"1097_CR66","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jamasurg.2020.3356","volume":"155","author":"EL Vos","year":"2020","unstructured":"Vos EL, Salo-Mullen EE, Tang LH, Schattner M, Yoon SS, Gerdes H, et al. Indications for total gastrectomy in CDH1 mutation carriers and outcomes of risk-reducing minimally invasive and open gastrectomies. JAMA Surg. 2020;155(11):1050\u20137. https:\/\/doi.org\/10.1001\/jamasurg.2020.3356.","journal-title":"JAMA Surg"},{"issue":"6","key":"1097_CR67","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/jso.27603","volume":"129","author":"G Corso","year":"2024","unstructured":"Corso G, Davis JL, Strong VE. Points to consider regarding prophylactic total gastrectomy in germline CDH1 variant carriers. J Surg Oncol. 2024;129(6):1082\u20138. https:\/\/doi.org\/10.1002\/jso.27603.","journal-title":"J Surg Oncol"},{"issue":"4","key":"1097_CR68","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/CEJ.0000000000000805","volume":"32","author":"JL Davis","year":"2023","unstructured":"Davis JL, Strong VE. Controversies and strengths in prophylactic total gastrectomy for germline CDH1 pathogenic variant carriers. Eur J Cancer Prev. 2023;32(4):308\u20139. https:\/\/doi.org\/10.1097\/CEJ.0000000000000805.","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"1097_CR69","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00535-020-01749-w","volume":"56","author":"BF Curtin","year":"2021","unstructured":"Curtin BF, Gamble LA, Schueler SA, Ruff SM, Quezado M, Miettinen M, et al. Enhanced endoscopic detection of occult gastric cancer in carriers of pathogenic CDH1 variants. J Gastroenterol. 2021;56(2):139\u201346. https:\/\/doi.org\/10.1007\/s00535-020-01749-w.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1097_CR70","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(22)00700-8","volume":"24","author":"CYC Lee","year":"2023","unstructured":"Lee CYC, Olivier A, Honing J, Lydon AM, Richardson S, O\u2019Donovan M, et al. Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study. Lancet Oncol. 2023;24(1):107\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(22)00700-8.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1097_CR71","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(23)00057-8","volume":"24","author":"B Asif","year":"2023","unstructured":"Asif B, Sarvestani AL, Gamble LA, Samaranayake SG, Famiglietti AL, Fasaye GA, et al. Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study. Lancet Oncol. 2023;24(4):383\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(23)00057-8.","journal-title":"Lancet Oncol"},{"key":"1097_CR72","unstructured":"NCCN Guidelines Version 1.2024 Gastric Cancer. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"issue":"10","key":"1097_CR73","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"1097_CR74","doi-asserted-by":"publisher","first-page":"175883592093035","DOI":"10.1177\/1758835920930359","volume":"12","author":"K Wang","year":"2020","unstructured":"Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, et al. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol. 2020;12:1758835920930359. https:\/\/doi.org\/10.1177\/1758835920930359.","journal-title":"Ther Adv Med Oncol."},{"issue":"10184","key":"1097_CR75","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"12","key":"1097_CR76","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17(12):1697\u2013708. https:\/\/doi.org\/10.1016\/S1470-2045(16)30531-9.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1097_CR77","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13(4):545\u20139.","journal-title":"Int J Mol Med"},{"issue":"5","key":"1097_CR78","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5): e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1097_CR79","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198. https:\/\/doi.org\/10.1038\/s41392-023-01460-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1097_CR80","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248\u201364. https:\/\/doi.org\/10.1016\/j.cell.2019.01.021.","journal-title":"Cell"},{"issue":"1","key":"1097_CR81","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12885-019-5322-0","volume":"19","author":"L Lian","year":"2019","unstructured":"Lian L, Li XL, Xu MD, Li XM, Wu MY, Zhang Y, et al. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer. 2019;19(1):183. https:\/\/doi.org\/10.1186\/s12885-019-5322-0.","journal-title":"BMC Cancer"},{"issue":"2","key":"1097_CR82","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/JCO.2004.00.3467","volume":"24","author":"S Juttner","year":"2006","unstructured":"Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006;24(2):228\u201340. https:\/\/doi.org\/10.1200\/JCO.2004.00.3467.","journal-title":"J Clin Oncol"},{"key":"1097_CR83","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1186\/1471-2407-10-659","volume":"10","author":"S Suzuki","year":"2010","unstructured":"Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor\u2014a expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. BMC Cancer. 2010;10:659. https:\/\/doi.org\/10.1186\/1471-2407-10-659.","journal-title":"BMC Cancer"},{"issue":"5","key":"1097_CR84","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.23.7537.","journal-title":"J Clin Oncol"},{"issue":"9911","key":"1097_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(13)61719-5.","journal-title":"Lancet"},{"issue":"11","key":"1097_CR86","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6.","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"1097_CR87","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1200\/JCO.2019.37.15_suppl.3143","volume":"37","author":"A Raimondi","year":"2019","unstructured":"Raimondi A, Gasparini P, Lonardi S, Corallo S, Fornaro L, Laterza MM, et al. Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric cancer (mGC): the VERA study. J Clin Oncol. 2019;37(15 Suppl):3143. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.3143.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1097_CR88","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdn169.","journal-title":"Ann Oncol"},{"issue":"8","key":"1097_CR89","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1172\/JCI32278","volume":"117","author":"H Zhang","year":"2007","unstructured":"Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007;117(8):2051\u20138. https:\/\/doi.org\/10.1172\/JCI32278.","journal-title":"J Clin Invest"},{"issue":"1","key":"1097_CR90","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39\u201351. https:\/\/doi.org\/10.1056\/NEJMra043186.","journal-title":"N Engl J Med"},{"issue":"9742","key":"1097_CR91","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"20","key":"1097_CR92","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a Novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"1097_CR93","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"issue":"2","key":"1097_CR94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mdi064","volume":"16","author":"M Tanner","year":"2005","unstructured":"Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdi064.","journal-title":"Ann Oncol"},{"issue":"1","key":"1097_CR95","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41598-020-58674-4","volume":"10","author":"L Sun","year":"2020","unstructured":"Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma C, et al. Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2083. https:\/\/doi.org\/10.1038\/s41598-020-58674-4.","journal-title":"Sci Rep"},{"issue":"10294","key":"1097_CR96","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"11","key":"1097_CR97","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"issue":"7890","key":"1097_CR98","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330. https:\/\/doi.org\/10.1038\/s41586-021-04161-3.","journal-title":"Nature"},{"issue":"4","key":"1097_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.152881","volume":"216","author":"X Liu","year":"2020","unstructured":"Liu X, Choi MG, Kim K, Kim KM, Kim ST, Park SH, et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol Res Pract. 2020;216(4): 152881. https:\/\/doi.org\/10.1016\/j.prp.2020.152881.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"1097_CR100","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1078-0432.CCR-23-1340","volume":"30","author":"CC Lu","year":"2024","unstructured":"Lu CC, Beckman RA, Li XN, Zhang W, Jiang Q, Marchenko O, et al. Tumor-agnostic approvals: insights and practical considerations. Clin Cancer Res. 2024;30(3):480\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1340.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1097_CR101","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.519.","journal-title":"Ann Oncol"},{"issue":"3","key":"1097_CR102","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bjs.10663","volume":"105","author":"K Polom","year":"2018","unstructured":"Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105(3):159\u201367. https:\/\/doi.org\/10.1002\/bjs.10663.","journal-title":"Br J Surg"},{"issue":"31","key":"1097_CR103","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","volume":"31","author":"A Ohtsu","year":"2013","unstructured":"Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935\u201343. https:\/\/doi.org\/10.1200\/JCO.2012.48.3552.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1097_CR104","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","volume":"14","author":"F Lordick","year":"2013","unstructured":"Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(13)70102-5.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1097_CR105","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(17)30566-1","volume":"18","author":"DVT Catenacci","year":"2017","unstructured":"Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(11):1467\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(17)30566-1.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1097_CR106","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamaoncol.2016.5580","volume":"3","author":"MA Shah","year":"2017","unstructured":"Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 2017;3(5):620\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5580.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1097_CR107","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1165\/rcmb.2013-0456OC","volume":"51","author":"MJ LaFemina","year":"2014","unstructured":"LaFemina MJ, Sutherland KM, Bentley T, Gonzales LW, Allen L, Chapin CJ, et al. Claudin-18 deficiency results in alveolar barrier dysfunction and impaired alveologenesis in mice. Am J Respir Cell Mol Biol. 2014;51(4):550\u20138. https:\/\/doi.org\/10.1165\/rcmb.2013-0456OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"23","key":"1097_CR108","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1097_CR109","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.21873\/anticanres.13919","volume":"39","author":"JH Baek","year":"2019","unstructured":"Baek JH, Park DJ, Kim GY, Cheon J, Kang BW, Cha HJ, et al. Clinical implications of Claudin182 expression in patients with gastric cancer. Anticancer Res. 2019;39(12):6973\u20139. https:\/\/doi.org\/10.21873\/anticanres.13919.","journal-title":"Anticancer Res"},{"issue":"9","key":"1097_CR110","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Tureci O. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49(9):870\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyz068.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"1097_CR111","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, Lotz G, Fanelli GN, Brignola S, Lanza C, Cappellesso R, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019;121(3):257\u201363. https:\/\/doi.org\/10.1038\/s41416-019-0508-4.","journal-title":"Br J Cancer"},{"issue":"16 Suppl","key":"1097_CR112","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2023.41.16_suppl.4035","volume":"41","author":"K Shitara","year":"2023","unstructured":"Shitara K, Xu R-H, Moran DM, Guerrero A, Li R, Pavese J, et al. Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). J Clin Oncol. 2023;41(16 Suppl):4035. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4035.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1097_CR113","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 182 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21(5):354\u201369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"1097_CR114","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01518-1","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024. https:\/\/doi.org\/10.1007\/s10120-024-01518-1.","journal-title":"Gastric Cancer"},{"key":"1097_CR115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin U, Schuler M, Richly H, Bauer S, Krilova A, Dechow T, et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018;100:17\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2018.05.007.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1097_CR116","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, Tureci O, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"issue":"10389","key":"1097_CR117","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"issue":"8","key":"1097_CR118","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"12","key":"1097_CR119","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736\u201342. https:\/\/doi.org\/10.1038\/bjc.2017.367.","journal-title":"Br J Cancer"},{"issue":"4 Suppl","key":"1097_CR120","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/JCO.2023.41.4_suppl.352","volume":"41","author":"R-H Xu","year":"2023","unstructured":"Xu R-H, Wei X, Zhang D, Qiu M, Zhang Y, Zhao H, et al. A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant\/refractory solid tumors. J Clin Oncol. 2023;41(4 Suppl):352. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.352.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1097_CR121","doi-asserted-by":"publisher","first-page":"A1288-A","DOI":"10.1136\/jitc-2023-SITC2023.1169","volume":"11","author":"M Gaspar","year":"2023","unstructured":"Gaspar M, Natoli M, Castan L, Rahmy S, Kelton C, Mulgrew K, et al. 1169 AZD5863: a specific, potent, affinity-optimized claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing. J Immunother Cancer. 2023;11(Suppl 1):A1288-A. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.1169.","journal-title":"J Immunother Cancer"},{"issue":"16 Suppl","key":"1097_CR122","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gong J, Lin R, Zhao S, Wang J, Wang Q, et al. First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors. J Clin Oncol. 2023;41(16 Suppl):3016. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3016.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1097_CR123","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1200\/JCO.2024.42.16_suppl.3028","volume":"42","author":"C Bai","year":"2024","unstructured":"Bai C, Xue J, Zheng Y, Sun M, Ying J, Zhou F, et al. A phase 1\/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric\/gastroesophageal junction cancer. J Clin Oncol. 2024;42(16 Suppl):3028. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3028.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1097_CR124","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"4","key":"1097_CR125","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.005.","journal-title":"Cancer Cell"},{"issue":"4","key":"1097_CR126","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111(4):409\u201318. https:\/\/doi.org\/10.1093\/jnci\/djy134.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1097_CR127","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189\u201398. https:\/\/doi.org\/10.1038\/s41591-022-01800-8.","journal-title":"Nat Med"},{"issue":"3 Suppl","key":"1097_CR128","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/JCO.2024.42.3_suppl.356","volume":"42","author":"GP Botta","year":"2024","unstructured":"Botta GP, Kelly RJ, Jin Z, Ma H, Ku GY, Zhao D, et al. CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: results of ELIMYN18.2 phase 1b clinical trial. J Clin Oncol. 2024;42(3 Suppl):356. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.356.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1097_CR129","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6.","journal-title":"Nat Rev Drug Discov"},{"key":"1097_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100604","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gong J, Sun Y, Yang S, Zhang M, Cui J, et al. 132P A phase I clinical trial of QLS31905 in advanced solid tumors. Immuno-oncol Technol. 2023. https:\/\/doi.org\/10.1016\/j.iotech.2023.100604.","journal-title":"Immuno-oncol Technol"},{"key":"1097_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116138","volume":"245","author":"Q Meng","year":"2024","unstructured":"Meng Q, Hao Y, Yang M, Du Y, Wang S. Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse. J Pharm Biomed Anal. 2024;245: 116138. https:\/\/doi.org\/10.1016\/j.jpba.2024.116138.","journal-title":"J Pharm Biomed Anal"},{"issue":"4 Suppl","key":"1097_CR132","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.2023.41.4_suppl.382","volume":"41","author":"W Yk","year":"2023","unstructured":"Yk W, Gong J, Sun Y, Zhang J, Ni S, Hou J, et al. Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. J Clin Oncol. 2023;41(4 Suppl):382. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1097_CR133","doi-asserted-by":"publisher","first-page":"9803","DOI":"10.1038\/s41598-022-13764-3","volume":"12","author":"J Huang","year":"2022","unstructured":"Huang J, Liu F, Li C, Liang X, Li C, Liu Y, et al. Role of CD47 in tumor immunity: a potential target for combination therapy. Sci Rep. 2022;12(1):9803. https:\/\/doi.org\/10.1038\/s41598-022-13764-3.","journal-title":"Sci Rep"},{"issue":"4 Suppl","key":"1097_CR134","doi-asserted-by":"publisher","first-page":"TPS765","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS765","volume":"41","author":"MJ Overman","year":"2023","unstructured":"Overman MJ, Melhem R, Blum-Murphy MA, Ramos C, Petrosyan L, Li J, et al. A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas. J Clin Oncol. 2023;41(4 Suppl):TPS765. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.TPS765.","journal-title":"J Clin Oncol"},{"key":"1097_CR135","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006704","author":"J Gao","year":"2023","unstructured":"Gao J, Wang Z, Jiang W, Zhang Y, Meng Z, Niu Y, et al. CLDN18.2 and 4\u20131BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-006704.","journal-title":"J Immunother Cancer"},{"key":"1097_CR136","doi-asserted-by":"publisher","first-page":"S631","DOI":"10.1016\/j.annonc.2023.09.2178","volume":"34","author":"G Ku","year":"2023","unstructured":"Ku G, Shen L, Klempner SJ, Pan H, Kratz J, Liang X, et al. 1039P First-in-human phase I study of givastomig, a novel Claudin 18.2\/4-1BB bispecific antibody in advanced solid tumors. Ann Oncol. 2023;34:S631. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2178.","journal-title":"Ann Oncol"},{"issue":"2","key":"1097_CR137","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116\u201329. https:\/\/doi.org\/10.1038\/nrc2780.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1097_CR138","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000441149","volume":"82","author":"N Han","year":"2015","unstructured":"Han N, Kim MA, Lee HS, Kim WH. Evaluation of fibroblast growth factor receptor 2 expression, heterogeneity and clinical significance in gastric cancer. Pathobiology. 2015;82(6):269\u201379. https:\/\/doi.org\/10.1159\/000441149.","journal-title":"Pathobiology"},{"issue":"11","key":"1097_CR139","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1634\/theoncologist.2019-0121","volume":"24","author":"SJ Klempner","year":"2019","unstructured":"Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, et al. FGFR2-altered gastroesophageal adenocarcinomas are an uncommon clinicopathologic entity with a distinct genomic landscape. Oncologist. 2019;24(11):1462\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2019-0121.","journal-title":"Oncologist"},{"key":"1097_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102650","author":"M Ratti","year":"2023","unstructured":"Ratti M, Orlandi E, Hahne JC, Vecchia S, Citterio C, Anselmi E, et al. Targeting FGFR pathways in gastrointestinal cancers: new frontiers of treatment. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11102650.","journal-title":"Biomedicines"},{"issue":"4","key":"1097_CR141","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/bjc.2013.802","volume":"110","author":"X Su","year":"2014","unstructured":"Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014;110(4):967\u201375. https:\/\/doi.org\/10.1038\/bjc.2013.802.","journal-title":"Br J Cancer"},{"issue":"4","key":"1097_CR142","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/bjc.2011.603","volume":"106","author":"K Matsumoto","year":"2012","unstructured":"Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 2012;106(4):727\u201332. https:\/\/doi.org\/10.1038\/bjc.2011.603.","journal-title":"Br J Cancer"},{"issue":"5","key":"1097_CR143","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673\u201384. https:\/\/doi.org\/10.1136\/gutjnl-2011-301839.","journal-title":"Gut"},{"issue":"11","key":"1097_CR144","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(22)00603-9.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1097_CR145","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","volume":"29","author":"S Ahn","year":"2016","unstructured":"Ahn S, Lee J, Hong M, Kim ST, Park SH, Choi MG, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol. 2016;29(9):1095\u2013103. https:\/\/doi.org\/10.1038\/modpathol.2016.96.","journal-title":"Mod Pathol"},{"issue":"8","key":"1097_CR146","first-page":"1373","volume":"2","author":"Y Hattori","year":"1996","unstructured":"Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res. 1996;2(8):1373\u201381.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1097_CR147","doi-asserted-by":"publisher","first-page":"1981202","DOI":"10.1080\/19420862.2021.1981202","volume":"13","author":"H Xiang","year":"2021","unstructured":"Xiang H, Chan AG, Ahene A, Bellovin DI, Deng R, Hsu AW, et al. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021;13(1):1981202. https:\/\/doi.org\/10.1080\/19420862.2021.1981202.","journal-title":"MAbs"},{"issue":"21","key":"1097_CR148","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1200\/JCO.19.01834","volume":"38","author":"DVT Catenacci","year":"2020","unstructured":"Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, et al. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J Clin Oncol. 2020;38(21):2418\u201326. https:\/\/doi.org\/10.1200\/JCO.19.01834.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1097_CR149","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","volume":"27","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024;27(3):558\u201370. https:\/\/doi.org\/10.1007\/s10120-024-01466-w.","journal-title":"Gastric Cancer"},{"issue":"16 Suppl","key":"1097_CR150","doi-asserted-by":"publisher","first-page":"TPS4164","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4164","volume":"40","author":"EC Smyth","year":"2022","unstructured":"Smyth EC, Chao J, Muro K, Yen P, Yanes RE, Zahlten-Kumeli A, et al. Trial in progress: phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101). J Clin Oncol. 2022;40(16 Suppl):TPS4164. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS4164.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1097_CR151","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc1647","volume":"5","author":"GW McLean","year":"2005","unstructured":"McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer\u2014a new therapeutic opportunity. Nat Rev Cancer. 2005;5(7):505\u201315. https:\/\/doi.org\/10.1038\/nrc1647.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1097_CR152","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s12276-020-0447-4","volume":"52","author":"JM Murphy","year":"2020","unstructured":"Murphy JM, Rodriguez YAR, Jeong K, Ahn EE, Lim SS. Targeting focal adhesion kinase in cancer cells and the tumor microenvironment. Exp Mol Med. 2020;52(6):877\u201386. https:\/\/doi.org\/10.1038\/s12276-020-0447-4.","journal-title":"Exp Mol Med"},{"key":"1097_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031726","author":"HH Chuang","year":"2022","unstructured":"Chuang HH, Zhen YY, Tsai YC, Chuang CH, Hsiao M, Huang MS, et al. FAK in cancer: from mechanisms to therapeutic strategies. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23031726.","journal-title":"Int J Mol Sci"},{"key":"1097_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.953938","volume":"12","author":"K Peng","year":"2022","unstructured":"Peng K, Li S, Li Q, Zhang C, Yuan Y, Liu M, et al. Positive Phospho-focal adhesion kinase in gastric cancer associates with poor prognosis after curative resection. Front Oncol. 2022;12: 953938. https:\/\/doi.org\/10.3389\/fonc.2022.953938.","journal-title":"Front Oncol"},{"issue":"4","key":"1097_CR155","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2353\/ajpath.2010.100172","volume":"177","author":"IR Lai","year":"2010","unstructured":"Lai IR, Chu PY, Lin HS, Liou JY, Jan YJ, Lee JC, et al. Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am J Pathol. 2010;177(4):1629\u201337. https:\/\/doi.org\/10.2353\/ajpath.2010.100172.","journal-title":"Am J Pathol"},{"issue":"1","key":"1097_CR156","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1158\/1078-0432.CCR-22-1609","volume":"29","author":"K Peng","year":"2023","unstructured":"Peng K, Zhang F, Wang Y, Sahgal P, Li T, Zhou J, et al. Development of combination strategies for focal adhesion kinase inhibition in diffuse gastric cancer. Clin Cancer Res. 2023;29(1):197\u2013208. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1609.","journal-title":"Clin Cancer Res"},{"issue":"30","key":"1097_CR157","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1038\/s41388-019-0850-2","volume":"38","author":"C Zhang","year":"2019","unstructured":"Zhang C, Stockwell SR, Elbanna M, Ketteler R, Freeman J, Al-Lazikani B, et al. Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4\/6 kinases. Oncogene. 2019;38(30):5905\u201320. https:\/\/doi.org\/10.1038\/s41388-019-0850-2.","journal-title":"Oncogene"},{"issue":"11","key":"1097_CR158","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1158\/1078-0432.CCR-20-3363","volume":"27","author":"JS Paradis","year":"2021","unstructured":"Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Gomes F, Arang N, et al. Synthetic lethal screens reveal cotargeting FAK and MEK as a multimodal precision therapy for GNAQ-driven uveal melanoma. Clin Cancer Res. 2021;27(11):3190\u2013200. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3363.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1097_CR159","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2021.05.018","volume":"75","author":"X Song","year":"2021","unstructured":"Song X, Xu H, Wang P, Wang J, Affo S, Wang H, et al. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. J Hepatol. 2021;75(4):888\u201399. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.018.","journal-title":"J Hepatol"},{"issue":"4","key":"1097_CR160","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/1535-7163.MCT-17-0561","volume":"17","author":"G Chen","year":"2018","unstructured":"Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, et al. Wnt\/beta-catenin pathway activation mediates adaptive resistance to braf inhibition in colorectal cancer. Mol Cancer Ther. 2018;17(4):806\u201313. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0561.","journal-title":"Mol Cancer Ther"},{"issue":"16 Suppl","key":"1097_CR161","doi-asserted-by":"publisher","first-page":"CT143","DOI":"10.1158\/1538-7445.Am2020-ct143","volume":"80","author":"R Shinde","year":"2020","unstructured":"Shinde R, Terbuch A, Little M, Caldwell R, Kurup R, Riisnaes R, et al. Abstract CT143: phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers. Cancer Res. 2020;80(16 Suppl):CT143. https:\/\/doi.org\/10.1158\/1538-7445.Am2020-ct143.","journal-title":"Cancer Res"},{"key":"1097_CR162","doi-asserted-by":"publisher","first-page":"1274209","DOI":"10.3389\/fphar.2024.1274209","volume":"15","author":"HH Hu","year":"2024","unstructured":"Hu HH, Wang SQ, Shang HL, Lv HF, Chen BB, Gao SG, et al. Roles and inhibitors of FAK in cancer: current advances and future directions. Front Pharmacol. 2024;15:1274209. https:\/\/doi.org\/10.3389\/fphar.2024.1274209.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1097_CR163","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","volume":"77","author":"T Shimizu","year":"2016","unstructured":"Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, et al. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(5):997\u20131003. https:\/\/doi.org\/10.1007\/s00280-016-3010-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"1097_CR164","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","volume":"27","author":"JC Soria","year":"2016","unstructured":"Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol. 2016;27(12):2268\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdw427.","journal-title":"Ann Oncol"},{"issue":"5","key":"1097_CR165","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investig New Drugs. 2015;33(5):1100\u20137. https:\/\/doi.org\/10.1007\/s10637-015-0282-y.","journal-title":"Investig New Drugs"},{"issue":"13","key":"1097_CR166","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","volume":"73","author":"N Ishii","year":"2013","unstructured":"Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 2013;73(13):4050\u201360. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3937.","journal-title":"Cancer Res"},{"issue":"5","key":"1097_CR167","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25(5):697\u2013710. https:\/\/doi.org\/10.1016\/j.ccr.2014.03.011.","journal-title":"Cancer Cell"},{"issue":"16 Suppl","key":"1097_CR168","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1200\/JCO.2023.41.16_suppl.5515","volume":"41","author":"SN Banerjee","year":"2023","unstructured":"Banerjee SN, Ring KL, Nieuwenhuysen EV, Fabbro M, Aghajanian C, Oaknin A, et al. Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: a phase 2 study of avutometinib (VS-6766) \u00b1 defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J Clin Oncol. 2023;41(16 Suppl):5515. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5515.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1097_CR169","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1200\/JCO.2024.42.16_suppl.4140","volume":"42","author":"K-H Lim","year":"2024","unstructured":"Lim K-H, Spencer KR, Safyan RA, Picozzi VJ, Varghese AM, Siolas D, et al. Avutometinib\/defactinib and gemcitabine\/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: initial safety and efficacy of phase 1b\/2 study (RAMP 205). J Clin Oncol. 2024;42(16 Suppl):4140. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4140.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1097_CR170","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"FX Yu","year":"2015","unstructured":"Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163(4):811\u201328. https:\/\/doi.org\/10.1016\/j.cell.2015.10.044.","journal-title":"Cell"},{"issue":"1","key":"1097_CR171","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-023-05568-8","volume":"14","author":"B Messina","year":"2023","unstructured":"Messina B, Lo Sardo F, Scalera S, Memeo L, Colarossi C, Mare M, et al. Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression. Cell Death Dis. 2023;14(1):21. https:\/\/doi.org\/10.1038\/s41419-023-05568-8.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1097_CR172","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s12253-014-9757-y","volume":"20","author":"X Hu","year":"2014","unstructured":"Hu X, Xin Y, Xiao Y, Zhao J. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathol Oncol Res. 2014;20(4):805\u201311. https:\/\/doi.org\/10.1007\/s12253-014-9757-y.","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"1097_CR173","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1002\/ijc.32667","volume":"146","author":"J Giraud","year":"2020","unstructured":"Giraud J, Molina-Castro S, Seeneevassen L, Sifre E, Izotte J, Tiffon C, et al. Verteporfin targeting YAP1\/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells. Int J Cancer. 2020;146(8):2255\u201367. https:\/\/doi.org\/10.1002\/ijc.32667.","journal-title":"Int J Cancer"},{"issue":"13","key":"1097_CR174","doi-asserted-by":"publisher","first-page":"16180","DOI":"10.18632\/oncotarget.7568","volume":"7","author":"J Zhang","year":"2016","unstructured":"Zhang J, Wang G, Chu SJ, Zhu JS, Zhang R, Lu WW, et al. Loss of large tumor suppressor 1 promotes growth and metastasis of gastric cancer cells through upregulation of the YAP signaling. Oncotarget. 2016;7(13):16180\u201393. https:\/\/doi.org\/10.18632\/oncotarget.7568.","journal-title":"Oncotarget"},{"issue":"1","key":"1097_CR175","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccell.2020.05.019","volume":"38","author":"Y Tang","year":"2020","unstructured":"Tang Y, Fang G, Guo F, Zhang H, Chen X, An L, et al. Selective inhibition of STRN3-containing PP2A phosphatase restores hippo tumor-suppressor activity in gastric cancer. Cancer Cell. 2020;38(1):115\u201328. https:\/\/doi.org\/10.1016\/j.ccell.2020.05.019. (e9).","journal-title":"Cancer Cell"},{"issue":"1","key":"1097_CR176","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12876-022-02386-8","volume":"22","author":"MH Wang","year":"2022","unstructured":"Wang MH, Li BZ, Chen Y, Wang J. TEADs serve as potential prognostic biomarkers and targets for human gastric cancer. BMC Gastroenterol. 2022;22(1):308. https:\/\/doi.org\/10.1186\/s12876-022-02386-8.","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"1097_CR177","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","volume":"26","author":"Y Liu-Chittenden","year":"2012","unstructured":"Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300\u20135. https:\/\/doi.org\/10.1101\/gad.192856.112.","journal-title":"Genes Dev"},{"issue":"58","key":"1097_CR178","doi-asserted-by":"publisher","first-page":"98887","DOI":"10.18632\/oncotarget.21946","volume":"8","author":"MH Kang","year":"2017","unstructured":"Kang MH, Jeong GS, Smoot DT, Ashktorab H, Hwang CM, Kim BS, et al. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1. Oncotarget. 2017;8(58):98887\u201397. https:\/\/doi.org\/10.18632\/oncotarget.21946.","journal-title":"Oncotarget"},{"issue":"2","key":"1097_CR179","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1158\/1535-7163.MCT-17-0560","volume":"17","author":"S Song","year":"2018","unstructured":"Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, et al. A Novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol Cancer Ther. 2018;17(2):443\u201354. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0560.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1097_CR180","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","volume":"25","author":"S Jiao","year":"2014","unstructured":"Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25(2):166\u201380. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.010.","journal-title":"Cancer Cell"},{"issue":"7350","key":"1097_CR181","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP\/TAZ in mechanotransduction. Nature. 2011;474(7350):179\u201383. https:\/\/doi.org\/10.1038\/nature10137.","journal-title":"Nature"},{"issue":"1","key":"1097_CR182","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1101\/gad.173435.111","volume":"26","author":"B Zhao","year":"2012","unstructured":"Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012;26(1):54\u201368. https:\/\/doi.org\/10.1101\/gad.173435.111.","journal-title":"Genes Dev"},{"issue":"18","key":"1097_CR183","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1242\/dev.070987","volume":"138","author":"K Wada","year":"2011","unstructured":"Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development. 2011;138(18):3907\u201314. https:\/\/doi.org\/10.1242\/dev.070987.","journal-title":"Development"},{"issue":"4","key":"1097_CR184","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nchembio.2036","volume":"12","author":"P Chan","year":"2016","unstructured":"Chan P, Han X, Zheng B, DeRan M, Yu J, Jarugumilli GK, et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat Chem Biol. 2016;12(4):282\u20139. https:\/\/doi.org\/10.1038\/nchembio.2036.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"1097_CR185","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.str.2015.11.005","volume":"24","author":"CL Noland","year":"2016","unstructured":"Noland CL, Gierke S, Schnier PD, Murray J, Sandoval WN, Sagolla M, et al. Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway signaling. Structure. 2016;24(1):179\u201386. https:\/\/doi.org\/10.1016\/j.str.2015.11.005.","journal-title":"Structure"},{"issue":"3","key":"1097_CR186","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.chembiol.2018.11.010","volume":"26","author":"K Bum-Erdene","year":"2019","unstructured":"Bum-Erdene K, Zhou D, Gonzalez-Gutierrez G, Ghozayel MK, Si Y, Xu D, et al. Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEAD\u22c5Yap protein\u2013protein interaction. Cell Chem Biol. 2019;26(3):378\u201389. https:\/\/doi.org\/10.1016\/j.chembiol.2018.11.010. (e13).","journal-title":"Cell Chem Biol"},{"key":"1097_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111767","volume":"184","author":"W Lu","year":"2019","unstructured":"Lu W, Wang J, Li Y, Tao H, Xiong H, Lian F, et al. Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors. Eur J Med Chem. 2019;184: 111767. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111767.","journal-title":"Eur J Med Chem"},{"issue":"12","key":"1097_CR188","first-page":"4399","volume":"10","author":"A Kaneda","year":"2020","unstructured":"Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein\u2013protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am J Cancer Res. 2020;10(12):4399\u2013415.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"1097_CR189","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","volume":"20","author":"TT Tang","year":"2021","unstructured":"Tang TT, Konradi AW, Feng Y, Peng X, Ma M, Li J, et al. Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma. Mol Cancer Ther. 2021;20(6):986\u201398. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0717.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1097_CR190","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s43018-021-00240-6","volume":"2","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Chiwaki F, Kojima S, Kawazu M, Komatsu M, Ueno T, et al. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer. 2021;2(9):962\u201377. https:\/\/doi.org\/10.1038\/s43018-021-00240-6.","journal-title":"Nat Cancer."},{"issue":"3","key":"1097_CR191","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47(3):250\u20136. https:\/\/doi.org\/10.1038\/ng.3218.","journal-title":"Nat Genet"},{"issue":"1","key":"1097_CR192","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell. 2020;37(1):104\u201322. https:\/\/doi.org\/10.1016\/j.ccell.2019.12.006. (e12).","journal-title":"Cancer Cell"},{"issue":"13 Suppl","key":"1097_CR193","doi-asserted-by":"publisher","first-page":"ND11","DOI":"10.1158\/1538-7445.Am2021-nd11","volume":"81","author":"AR Macleod","year":"2021","unstructured":"Macleod AR. Abstract ND11: The discovery and characterization of ION-537: a next generation antisense oligonucleotide inhibitor of YAP1 in preclinical cancer models. Cancer Res. 2021;81(13 Suppl):ND11. https:\/\/doi.org\/10.1158\/1538-7445.Am2021-nd11.","journal-title":"Cancer Res"},{"issue":"19","key":"1097_CR194","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202200303","volume":"17","author":"P Furet","year":"2022","unstructured":"Furet P, Bordas V, Le Douget M, Salem B, Mesrouze Y, Imbach-Weese P, et al. The first class of small molecules potently disrupting the YAP-TEAD interaction by direct competition. ChemMedChem. 2022;17(19): e202200303. https:\/\/doi.org\/10.1002\/cmdc.202200303.","journal-title":"ChemMedChem"},{"issue":"11","key":"1097_CR195","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300051","volume":"18","author":"H Sellner","year":"2023","unstructured":"Sellner H, Chapeau E, Furet P, Voegtle M, Salem B, Le Douget M, et al. Optimization of a class of dihydrobenzofurane analogs toward orally efficacious YAP-TEAD protein\u2013protein interaction inhibitors. ChemMedChem. 2023;18(11): e202300051. https:\/\/doi.org\/10.1002\/cmdc.202300051.","journal-title":"ChemMedChem"},{"key":"1097_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00754-9","author":"EA Chapeau","year":"2024","unstructured":"Chapeau EA, Sansregret L, Galli GG, Chene P, Wartmann M, Mourikis TP, et al. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer. 2024. https:\/\/doi.org\/10.1038\/s43018-024-00754-9.","journal-title":"Nat Cancer."},{"issue":"16 Suppl","key":"1097_CR197","doi-asserted-by":"publisher","first-page":"TPS3168","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3168","volume":"40","author":"AW Tolcher","year":"2022","unstructured":"Tolcher AW, Lakhani NJ, McKean M, Lingaraj T, Victor L, Sanchez-Martin M, et al. A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors. J Clin Oncol. 2022;40(16 Suppl):TPS3168. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS3168.","journal-title":"J Clin Oncol"},{"issue":"8 Suppl","key":"1097_CR198","doi-asserted-by":"publisher","first-page":"CT006","DOI":"10.1158\/1538-7445.Am2023-ct006","volume":"83","author":"TA Yap","year":"2023","unstructured":"Yap TA, Kwiatkowski DJ, Desai J, Dagogo-Jack I, Millward M, Kindler HL, et al. Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. Cancer Res. 2023;83(8 Suppl):CT006. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-ct006.","journal-title":"Cancer Res"},{"issue":"6","key":"1097_CR199","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.4251\/wjgo.v14.i6.1162","volume":"14","author":"C Diaz Del Arco","year":"2022","unstructured":"Diaz Del Arco C, Estrada Munoz L, Ortega Medina L, Molina Roldan E, Ceron Nieto MA, Garcia Gomez de Las Heras S, et al. Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer. World J Gastrointest Oncol. 2022;14(6):1162\u201374. https:\/\/doi.org\/10.4251\/wjgo.v14.i6.1162.","journal-title":"World J Gastrointest Oncol."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01097-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01097-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01097-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:06:25Z","timestamp":1731474385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01097-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":199,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1097"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01097-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"30 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LWW is supported by the NIH\/NCI Molecular Oncology Training Program (5T32CA203703-09), and RHM is supported by grants from the NIH (K08CA263304) and Gastric Cancer Foundation. This publication is supported by NIH\/NCI Cancer Center Support Grant P30CA013696.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lawrence W. Wu, Sung Joo Jang, Cameron Shapiro, Ladan Fazlollahi, and Timothy C. Wang have no relevant conflicts of interest to declare that may be relevant to the contents of this article. Sandra W. Ryeom has undertaken consulting work for AttisLab and has received research support from ImmPACT Bio. Ryan H. Moy has undertaken consulting work for Puretech Health, served on the Advisory Board for IDEAYA Biosciences and Nimbus Therapeutics, and has received research funding, paid to the institution, from Nimbus Therapeutics and Repare Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent to the publication of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LWW and RHM proposed the review topic. LWW wrote the original draft of this article. LF provided representative images of diffuse-type and intestinal-type gastric cancer. All authors have reviewed, revised, and provided critical feedback on the manuscript, and provided final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}